Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia

Blood

Volumn 105, Issue 8, 2005, Pages 3019-3025

  Sanz, Miguel A ^a   Tallman, Martin S ^b   Lo Coco, Francesco ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTHRACYCLINE DERIVATIVE; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CORTICOSTEROID; DEXAMETHASONE; HEPARIN; IDARUBICIN; MANNITOL; MERCAPTOPURINE; METHOTREXATE; OSMOTIC DIURETIC AGENT; RETINOIC ACID; TRANEXAMIC ACID;

ACUTE KIDNEY FAILURE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BRAIN PSEUDOTUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER REGRESSION; CARDIOPULMONARY INSUFFICIENCY; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOGENETICS; DIAGNOSTIC ACCURACY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EARLY DIAGNOSIS; FIBRINOGEN BLOOD LEVEL; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HEADACHE; HEALTH SURVEY; HEART ARRHYTHMIA; HEART RATE VARIABILITY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; IMMUNOPHENOTYPING; INTRACRANIAL PRESSURE; LEUKEMOGENESIS; LEUKOCYTOSIS; LUNG INFILTRATE; MEDICAL INFORMATION; NAUSEA AND VOMITING; PAPILLEDEMA; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PREGNANCY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RETINOIC ACID SYNDROME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VISUAL IMPAIRMENT; WEIGHT GAIN;

EID: 17044401059     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-09-3475     Document Type: Review

References (47)

1. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100:4298-4302.
2. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90:1014-1021.
3. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol. 1998;16:78-85.
4. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH, on behalf of the MRC Adult Leukemia Working Party. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood. 1999;93:4131-4143.
5. Fenaux P, Chastang C, Sanz MA, et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:1192-1200.
6. Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood. 1999;94:3015-3021.
7. Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia. 2000;14:1362-1370.
8. Sanz M, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237-1243.
9. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759-767.
10. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia. 2003;17:1454-1463.
11. Sanz MA, Martín G, Lo Coco F. Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukemia. Baillieres Best Pract Res Clin Haematol. 2003;16:433-451.
12. Douer D. New advances in the treatment of acute promyelocytic leukemia. Int J Hematol. 2002; 76(Suppl 2):179-187.
13. Tallman MS, Brenner B, de la Serna J, et al. APL coagulopathy workshop, 21 January 2004, London, England. Leuk Res. 2005;29:347-351.
14. Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood. 1998;91:3093-3102.
15. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999;94:12-22.
16. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia. 2002;16:1959-1973.
17. Orfao A, Ortun̄o F, de Santiago M, Lopez A, San Miguel JF. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry. 2004:58A:62-71.
18. Orfao A, Chillon MC, Bortoluci AM, et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML/RARalpha gene rearrangements. Haematologica. 1999;84:405-412.
19. Cheson BD, Bennett JM, Kopecky K, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649.
20. Dyck JA, Warrell RP Jr, Evans RM, Miller WH Jr. Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein. Blood. 1995;86:862-867.
21. Falini B, Flenghi L, Fagioli M, et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (Anti-PML). Blood. 1997;90:4046-4053.
22. Villamor N, Costa D, Aymerich M, et al. Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3. Am J Clin Pathol. 2000;114:786-792.
23. Gomis F, Sanz J, Sempere A, et al. Immunofluorescent analysis with the anti-pml monoclonal antibody (PG-M3) for rapid and accurate genetic diagnosis of acute promyelocytic leukemia. Ann Hematol. 2004;83:687-690.
24. Shen Z, Shi Z, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101;5328-8335.
25. Hiorns LR, Swansbury J, Mehta J, et al. Additional chromosomal abnormalities confer worse prognosis in acute promyelocytic leukemia. Br J Haematol. 1997;96:314-321.
26. De Botton, S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities have no effect on the clinical outcome of patients with acute promyelocytic leukemia. Br J Haematol. 2000;111:801-806.
27. Hernández JM, Martín G, Gutiérrez NC, et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica. 2001;86:807-813.
28. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med. 1994;120:278-286.
29. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia. 1995;9:774-778.
30. Breccia M, Diverio D, Noguera NI, et al. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. Haematologica. 2004;89:29-33.
31. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
32. Muindi J, Frankel SR, Miller WH, et al. Continuous treatment with all-trans RA progressively decreases plasma drug concentrations: implications for relapse and resistance in acute promyelocytic leukemia. Blood. 1992;79:299-307.
33. Diverio D, Rossi V, Avvisati G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood. 1998;92:784-789.
34. Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood. 2001;98:2651-2656.
35. Sanz MA, Vellenga E, Rayon C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004;104:3490-3493.
36. De Botton S, Coiteux V, Chevret S, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2004;22:1404-1412.
37. Testi AM, Lo Coco F, Biondi A, et al. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed promyelocytic leukemia in children. Blood. Prepublished January 27, 2005; DOI 10.1182/blood-2004-05-1971.
38. Ortega JJ, Martin G, Madero L, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy in children with acute promyelocytic leukemia: a multicenter study by the PETHEMA group. Blood. 2003;102(Suppl 1): 619a.
39. Mahmoud HH, Hurwitz CA, Roberts WM, et al. Tretinoin toxicity in children with acute promyelocytic leukemia. Lancet. 1993;342:1394-1395.
40. Giagounidis AAN, Beckmann MW, Giagounidis AS, et al. Acute promyelocytic leukemia and pregnancy. Eur J Haematol. 2000;64:267-271.
41. Fadilah SAW, Hatta AZ, Keng CS, Jamil MA, Singh S. Successful treatment of acute promyelocytic leukemia in pregnancy with all-trans retinoic acid. Leukemia. 2001;15:1665-1666.
42. Lipovsky MM, Biesma DH, Christiaens GC, Petersen EJ. Successful treatment of acute promyelocytic leukemia with all-trans retinoic acid during late pregnancy. Br J Haematol. 1996;94:699-701.
43. Terada Y, Shindo T, Endoh A, Watanabe M, Fukaya T, Yajima A. Fetal arrhythmia during treatment of pregnancy-associated acute promyelocytic leukemia with all-trans retinoic acid and favourable outcome. Leukemia. 1997;11:454-455.
44. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94:3315-3324.
45. Soignet S, Frankel S, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.
46. Camacho L, Soignet S, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol. 2000;18:2620-2625.
47. Barbey J, Pezzullo J, Soignet S. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J. Clin Oncol. 2003;21:3609-3615.